Skip to content

Celcuity CELC Total Liabilities

Total Liabilities at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.64B+44.4%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$57.43M-26.6%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$295.31M+356%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$44.29M-58.8%
CG Oncology logo
CG OncologyCGON
$43.48M+85.6%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$911.26M+170%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's total liabilities?
Celcuity (CELC) reported total liabilities of $356.64M in Q1 2026.
How has Celcuity's total liabilities changed year-over-year?
Celcuity's total liabilities increased by 171.3% year-over-year, from $131.46M to $356.64M.
What is the long-term trend for Celcuity's total liabilities?
Over 5 years (2020 to 2025), Celcuity's total liabilities has grown at a 211.2% compound annual growth rate (CAGR), from $1.25M to $366M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.